Latest Hikma News & Updates

See the latest news and media coverage for Hikma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Hikma

Global generics and specialty pharmaceutical company

hikma.com

Headquarters: London, United Kingdom
Founded year: 1978
Company type: Public company
Number of employees: 5,000–15,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Hikma

In short: Hikma won a landmark US Supreme Court patent case, reported strong financial growth, and invested $267 million in US manufacturing.

Company announcements

Today Hikma

Hikma launches Glucentra generic semaglutide in Saudi Arabia

Glucentra is the first generic semaglutide available to patients in the Kingdom. Hikma serves as exclusive commercialization partner for MENA.

September 9 Hikma

Hikma secures global regulatory review for an investigational medicine

Regulatory authorities in North America and Europe will evaluate the drug as the company expands affordable patient access worldwide.

August 6 Hikma

Hikma reports solid H1 results and reiterates outlook

Revenue grew 4% to $1,728m, core operating profit rose 9%, and the interim dividend increased 6%.

July 6 Hikma

Hikma launches XCOPRI cenobamate tablets in the UAE

The first anti-seizure medication with Cenobamate in the UAE treats partial-onset seizures in adults.

Media coverage

September 6 Ad hoc news

Hikma stock draws support from a Reuters contract report

Hikma Pharmaceuticals PLC (GB00B128J450) is in the spotlight after a Reuters report via TradingView on September 6, 2026 tied a Ras Al-Hikma earthworks contract worth...

September 4 Law360

Justices' Hikma Reasoning May Extend Well Beyond Pharma - Law360

The active steps framework announced by the U.S. Supreme Court in its Hikma v. Amarin decision, finding that Amarin failed to plausibly allege inducement of...

August 28 The Globe and Mail

Hikma completes $250m share buyback, reshaping capital structure

The latest announcement is out from Hikma Pharmaceuticals ( (GB:HIK) ).

August 22 The Globe and Mail

Hikma Pharmaceuticals Balances Strong H1 With Cautious Outlook

Detailed price information for Hikma Pharmaceuticals Plc (HKMPF) from The Globe and Mail including charting and trades.

Never miss news about Hikma

Track Hikma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Hikma competitors & trending companies

Browse news for competitors to Hikma and other trending companies.